Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
IFNG expression
Cancer:
Urothelial Cancer
Drug Class:
PD-L1 inhibitor
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Am J Transl Res
Title:
The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response
Published date:
07/12/2023
Excerpt:
The expression of CXCL9, IFNG, and GBP5 was independently associated with the response to anti-PD-L1 immunotherapy in patients with mUC.
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login